Changes in chromatin environment (mutations, translocations, epigenetic changes) are initiating factors of uncontrolled cell growth / oncogenesis. Chroma Target wishes from an improved understanding of the malignant chromatin environment new, more specific therapeutic strategies (less side effects) and lead compounds against a subset of cancers with a poor prognosis (T-cell progenitor acute lymphoblastic leukemia (ETP-ALL), MLL fusion develop mediated leukemia, medulloblastoma). Comparing 'omics' data will also allow gepersonaliiseerde medicine through identification of specific biomarkers.